10-Q · November 14, 2024
Lipella reported Q3 grant revenue of $80,380 and a net loss of $1,444,637 (EPS $(1.29)), continuing large operating losses driven by R&D and G&A. Cash fell to $1,353,734 at September 30, 2024, and management discloses…
Earnings analysis · 10-K
LIPO earnings analysis
Filed March 28, 2025 · Our reading of the company's report
The latest report
Lipella is a clinical-stage biotech pursuing reformulations of approved APIs using a proprietary metastable liposome Platform, with lead programs LP-10 (hemorrhagic cystitis) and LP-310 (oral lichen planus) advancing…
Read full summary
Lipella is a clinical-stage biotech pursuing reformulations of approved APIs using a proprietary metastable liposome Platform, with lead programs LP-10 (hemorrhagic cystitis) and LP-310 (oral lichen planus) advancing through Phase 2 programs. The company holds multiple issued patents (U.S., EU, Canada, Australia) with expirations in 2034–2035, has orphan designations for key programs, but remains pre-commercial, burning cash and issuing preferred/warrant financings to fund operations.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Gross margin
- 100.0%
What stood out
-
Proprietary Platform with issued patents
Lipella’s metastable liposome Platform is covered by issued U.S., European, Canadian and Australian patents — U.S. patents for LP-10 expire July 11, 2035 and November 9, 2034 and the European/Canadian/Australian patents expire October 22, 2034 (filing).
-
LP-10 completed Phase 2a (albeit small)
LP-10 completed a Phase 2a open-label dose-escalation trial in 13 subjects (trial commenced Feb 15, 2021; top-line results reported Q1 2023) and the company intends to pursue accelerated regulatory pathways (filing).
-
LP-310 Phase 2a advancing with favorable tolerability
LP-310 Phase 2a dose‑escalation initiated in 2024; the first cohort of eight participants received 0.25 mg with no product‑related serious adverse events and whole‑blood tacrolimus levels were undetectable or minimal; trial expected to complete in Q2 2025 and topline selected for presentation May 15, 2025 (filing).
-
Orphan designations for key programs
The company has received FDA orphan drug designation for LP-10 and for tacrolimus in LP-410 (LP-410 orphan designation dated November 11, 2023) which supports potential exclusivity benefits (filing).
-
Market opportunity quantified
Management estimates U.S. incidence of hemorrhagic cystitis in the range of approximately 100,000 to 200,000 cases per year and cites ~60,000 severe radiation‑induced and ~60,000 chemotherapy‑induced HC cases annually (filing).
-
Recent equity financings completed
Per recent 8‑K disclosures, aggregate Series B sales to date total 71,115 shares at $100 per share; the March 3, 2025 Third Closing raised $3,788,000 gross ($3,124,040 net) and the March 18, 2025 Final Closing raised $88,500 gross ($73,455 net) (8‑K filings).
What to watch
-
Pre-commercial, no meaningful product revenue
The company states it has not commercialized any products and 'does not expect to generate revenue from sales of any product candidates for several years' (filing).
-
Material cash burn / negative margins
Quarterly financial history shows deeply negative operating margins (e.g., Q4 2024 operating margin reported at -835.7% and Q3 2024 at -1815.6%) and a large free cash flow outflow in 2023Q4 of -$727,710, evidencing high cash burn (quarterly history provided).
-
Dilution and contingent share obligations from financings
Recent financing economics include issuance of Series B/C preferred shares, Placement Agent warrants and contingent Series C share issuances (e.g., 441,933 Series C shares and placement agent warrants tied to the March 3, 2025 closing), and aggregate Series B sold of 71,115 shares at $100 per share (8‑K filings), creating dilution risk (8‑K filings).
-
Registration-failure penalty could require share issuance
Under the March Offering arrangements, registration-failure penalties could require issuance of pro rata portions of 100,000 common shares (or cash) to March Investors or Spartan if registration deadlines (30/60 days) are not met (8‑K / prior analysis).
-
Limited clinical evidence to date
Lead LP-10 Phase 2a evidence is from a 13-subject trial and LP-310's first cohort is eight patients at 0.25 mg, so efficacy evidence is limited and pivotal trials will be required to support approval (filing).
-
Patent life limited without extensions
Key issued patents for LP-10 and LP-310 expire between October 22, 2034 and July 11, 2035 unless extended for regulatory delay (up to 14 years), limiting exclusivity horizon absent extensions (filing).
Management's outlook
10‑K contains no explicit numeric revenue or EPS guidance; management states product sales are not expected for several years and annual outlook is deferred to quarterly earnings press releases / calls.
Earlier filings 4
10-Q · August 13, 2024
Lipella reported Q2 (three months ended June 30, 2024) grant revenue of $136,431, up from $106,676 in Q2 2023, while operating loss narrowed to $952,189 from $1,575,200 a year earlier. Cash fell materially to $1,186,506…
10-Q · May 9, 2024
Lipella reported Q1 revenue of $145,880 (grant revenue), up from $118,048 in Q1 2023, but continued to generate operating losses; net loss was $1,191,809 for the quarter. Cash fell to $2,105,299 at March 31, 2024 and…
10-K · March 31, 2023
Lipella Pharmaceuticals is a clinical-stage biotech focused on reformulating approved generic active agents (tacrolimus) using a proprietary metastable liposome delivery Platform. The company completed a 13-subject…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.